Sort
50,496 grants matching “lung cancer”
Common targeting of the prostacyclin-PPARy axis in COPD and lung cancer
$580,374Rubin M Tuder · University Of Colorado Denver · R01 · FY2014 · CA
PennPET Explorer Scanner With Scalable Axial Length for Total Body PET Imaging
$580,347Joel S Karp · University Of Pennsylvania · R01 · FY2023 · CA
Therapy for Metastatic breast cancer based on micro RNA silencing
$580,298Anna Moore · Michigan State University · R01 · FY2021 · CA
Computer Support for the Colon Cancer Screening in PLCO Cancer Screening Trials
$580,268William Lake · Information Management Services, Inc. · N02 · FY2009 · CA
TCR signaling and cell cycle regulation in tumor-specific CD8 T cell dysfunction
$580,177Mary Philip · Vanderbilt University Medical Center · R37 · FY2022 · CA
Carbon Nanotube X-Ray for in-vivo Cancer and Detection and Treatment
$580,138Otto Z Zhou · Univ Of North Carolina Chapel Hill · U54 · FY2008 · CA
Autologous Lung Multipotent Stromal Cell Therapy for Emphysema
$580,117Edward P Ingenito · Brigham And Women'S Hospital · R01 · FY2016 · HL
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
$580,098Chad V Pecot · Univ Of North Carolina Chapel Hill · R01 · FY2025 · CA
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors
$580,072Kevan C Herold · Yale University · R01 · FY2021 · CA
HEI COMBINED PET CT SCANNER: CANCER:PROSTATE, LUNG, BREAST, &CERVICAL
$580,000Washington University · S10 · FY2005 · RR
Ultrasensitive Detection of Tumor Specific DNA Methylation Changes for the Early Detection of Lung CancerÂ
$579,985James G. Herman · University Of Pittsburgh At Pittsburgh · U01 · FY2018 · CA
SWOG Community Clinical Oncology Program Research Base
$579,978Charles D. Blanke · Oregon Health & Science University · U10 · FY2014 · CA
Dose-distribution radiomics to predict morbidity risk in radiotherapy
$579,921Joseph O Deasy · Sloan-Kettering Inst Can Research · R01 · FY2019 · CA
Explaining Variations in End-of-Life Care Intensity
$579,847Nancy L Keating · Harvard Medical School · R01 · FY2012 · CA
PHAGOCYTOSIS--PULMONARY ALVEOLAR MACROPHAGES
$579,843Brigham And Women'S Hospital · R01 · FY2001 · HL
Epigenetic and immunologic aspects of neuroendocrine cancers
$579,811Nitin Roper · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Integrating Evidence-Based Smoking Cessation Interventions into Lung Cancer Screening Programs: A Randomized Trial
$579,791Kathryn L Taylor · Georgetown University · R01 · FY2019 · CA
Targeting myeloid suppression to enhance anti-tumor immunity in breast cancer
$579,770Evanthia Theodosiou Roussos Torres · University Of Southern California · R01 · FY2023 · CA
Core B: Clinical Core
$579,763Joel L Weissfeld · University Of Pittsburgh At Pittsburgh · P50 · FY2012 · CA
Analyses of human T regulatory cells
$579,726Kwong Yok Tsang · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Identification of human tumor-associated antigens
$579,726Kwong Yok Tsang · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Development Of Drugs Acting At Adenosine Receptors
$579,661Kenneth Alan Jacobson · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2016 · DK
Computational modeling of tumor burden by CT to advance cancer therapeutics
$579,655Michael L. Maitland · Inova Health Care Services · R01 · FY2016 · CA
PHASE 0 TRIAL OF ITRACONAZOLE FOR EARLY-STAGE NON-SMALL CELL LUNG CANCER
$579,618The University Of Texas Southwestern Medical Center · · FY2014 · Department of the Army
(7) Novel imaging devices for measurement and control of tumor microenvironments
$579,582David Entenberg · Albert Einstein College Of Medicine · R01 · FY2020 · CA